Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

104
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

121
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
121
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

75
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
75
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

119
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
119
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

194
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
194
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

912
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
912

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polygenic risk in early-onset coronary artery disease with low prevalence of traditional cardiovascular risk factors.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Abnormal conduction-induced cardiomyopathy: a poorly explored entity.

European heart journal supplements : journal of the European Society of Cardiology·2024
Same author

The Prognostic impact of treatments evolution in STEMI.

International journal of cardiology·2023
Same author

COVID-19-Related Myocarditis: Are We There Yet? A Case Report of COVID-19-Related Fulminant Myocarditis.

Biomedicines·2023
Same author

The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2023
Same author

How Coronary Perforation Looks at Optical Coherence Tomography Imaging.

The Journal of invasive cardiology·2023

Related Experiment Video

Updated: Nov 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K

Left ventricle pacing challenges in cardiac resynchronization therapy systems.

Franco Zoppo1, Giulia Gagno2

  • 1Elettrofisiologia, Unità di Cardiologia, Ospedale Civile Gorizia (Italy) Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Italy.

Indian Pacing and Electrophysiology Journal
|April 16, 2021
PubMed
Summary

Left ventricle (LV) pacing presents unique challenges, including lead stability and capture confirmation. New approaches like His bundle pacing (HBP) and left bundle branch pacing (LBBP) offer potential for improved cardiac resynchronization therapy (CRT).

Keywords:
Left Ventricle Pacing Challenges

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.2K
Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

2.8K

Related Experiment Videos

Last Updated: Nov 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.2K
Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

2.8K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Left ventricle (LV) pacing is complex due to epicardial lead placement and potential instability.
  • Current LV capture confirmation relies on evoked response (ER) and LV pace to right ventricular (RV) sense algorithms.
  • Anodal capture and LV threshold variations can impact cardiac resynchronization therapy (CRT) effectiveness.

Purpose of the Study:

  • To review challenges in LV pacing, including lead stability, capture confirmation, and threshold variability.
  • To explore emerging techniques like His bundle pacing (HBP) and left bundle branch pacing (LBBP) for CRT.
  • To discuss management of issues like phrenic nerve stimulation (PNS) and suboptimal pacing timing.

Main Methods:

  • Literature review of current and emerging LV pacing technologies and algorithms.
  • Discussion of clinical implications of anodal capture and LV threshold behavior.
  • Analysis of new pacing strategies for improved CRT delivery and prevention of pacing-induced cardiomyopathy.

Main Results:

  • Bipolar LV leads have resolved anodal RV capture, but unintentional LV anodal capture is a new consideration.
  • LV threshold instability can lead to ineffective CRT, requiring careful management.
  • HBP and LBBP show promise for direct CRT and preventing pacing-induced cardiomyopathy.

Conclusions:

  • LV pacing requires addressing unique lead interface and stability challenges.
  • Emerging pacing strategies like HBP and LBBP offer promising alternatives for CRT.
  • Optimizing pacing parameters and exploring new techniques are crucial for effective CRT and patient outcomes.